Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



GlaxoSmithKline Begins Phase 3 Melanoma Study

Pharmaceutical giant GlaxoSmithKline (NYSE: GSK  ) announced in a press release that it has begun a phase 3 study to find out whether two of its drugs -- its BRAF inhibitor dabrafenid and MEK inhibitor trametinib -- can combine to work as a successful therapy for melanoma.

The study, which GSK has dubbed COMBI-AD, will determine if the combination of the two drugs can delay or prevent melanoma from recurring in patients who have had surgery to remove certain types of mutation-positive melanoma. GSK is currently competing with fellow pharmaceutical firm Roche (NASDAQOTH: RHHBY  ) to develop combination therapies for the disease; Roche is currently undergoing late-stage trials of a different combination of an MEK inhibitor and BRAF inhibitor of its own.

GSK's head of oncology research and development, Dr. Rafael Amado, was quoted in the press release as saying, "Given the efficacy and safety findings observed with combined dabrafenib-trametinib treatment in the metastatic setting, we are investigating whether the combination administered after surgery can help these patients live longer without melanoma recurrence."


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2233772, ~/Articles/ArticleHandler.aspx, 9/27/2016 2:59:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,220.19 125.36 0.69%
S&P 500 2,158.36 12.26 0.57%
NASD 5,303.55 46.06 0.88%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 2:43 PM
GSK $43.27 Up +0.31 +0.72%
GlaxoSmithKline CAPS Rating: ***
RHHBY $31.37 Up +0.20 +0.63%
Roche Holding Ltd.… CAPS Rating: *****